In The News

The Myeloma Crowd Multiple Myeloma Research, Funding, News, Tips and Help

  • Myeloma 101: How is Active Multiple Myeloma Defined?
    by Jenny A on January 24, 2020 at 4:44 am

    How is active myeloma defined? CRAB In the past, multiple myeloma was defined by four important “CRAB” features: Calcium, Renal, Anemia, and Bone Lesions. Each of these helps determine if you have myeloma in addition to a higher-than-normal monoclonal protein.   Calcium: Calcium levels that are 1 mg/dl above normal levels or over 11 mg/dl Renal […]

  • Multiple Myeloma Treatment and Secondary Cancers
    by Paul Kleutghen on January 24, 2020 at 1:37 am

    It is fair to say that, from multiple myeloma chat groups, support groups, blogs, etc. we have heard or read stories (or, heaven forbid, from personal experience) that fellow patients have come down with a ‘treatment related secondary cancer’. In our case, the majority of those will be skin cancers (basal and squamous cell carcinomas), […]

  • Connect With the Myeloma Crowd On Social Media: Together We’re Stronger
    by Allyse Shumway on January 24, 2020 at 12:51 am

    The Myeloma Crowd has numerous ways to connect with other patients and caregivers. We believe that when we are together, we are stronger. Everyone has a story and through our social media channels you can connect with patients on a similar journey as you.  Interested in sharing your myeloma story? Email info@crowdcare.org with your myeloma […]

  • Our Next Show: Multiple Myeloma Innovation in 2020 with Robert Orlowski, MD, PhD, MD Anderson Thursday, January 30, 2020 @ 11 am Central
    by Jenny A on January 23, 2020 at 4:09 am

    Thursday, January 30 @ 9 am Pacific, 10 am Mountain, 11 am Central, Noon Eastern Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer What innovation is coming in 2020 in myeloma research? Dr. Robert Orlowski of the the MD Anderson Cancer Center shares the insights learned from the recent […]

  • What is HealthTree® for Multiple Myeloma?
    by Allyse Shumway on January 22, 2020 at 9:31 pm

    Join HealthTree Today What is HealthTree? HealthTree is a free, new tool created by myeloma patients for myeloma patients. HealthTree is an online tool myeloma patients can use to navigate their care while also helping advance a cure. HealthTree empowers patients with myeloma knowledge, connects them to peers in similar situations and identifies personalized […]

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
    by Marisa Wexler, MS on January 27, 2020 at 1:00 pm

    Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of isatuximab when measuring levels of monoclonal protein — a marker of disease severity — in a person’s blood. Myeloma is a cancer of plasma cells, the type of cell responsible for making antibodies, or proteins that The post Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy appeared first on Myeloma Research News.

  • FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma
    by Patricia Inacio, PhD on January 24, 2020 at 3:00 pm

    The U.S. Food and Drug Administration (FDA) has granted priority review status to GlaxoSmithKline‘s application seeking the approval of belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company announced in a press release. The biologics license application (BLA) is specifically asking for belantamab’s approval for people with relapsed or refractory disease who received prior treatment The post FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma appeared first on Myeloma Research News.

  • Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients
    by Patricia Inacio, PhD on January 21, 2020 at 3:29 pm

    The European Commission has approved Darzalex (daratumumab), in combination with standard pre-transplant therapy, to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT). The decision follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, in December, recommending the approval of Darzalex in combination with Velcade (bortezomib), thalidomide, and The post Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients appeared first on Myeloma Research News.

  • NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients
    by David Melamed on January 20, 2020 at 1:00 pm

    NexImmune will soon initiate a Phase 1/2 trial evaluating its cell therapy NEXI-002 in people with multiple myeloma who failed three or more prior lines of therapy, the company announced. The announcement comes after the U.S. Food and Drug Administration cleared NexImmune’s investigational new drug (IND) application for NEXI-002, allowing it to enter clinical testing The post NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients appeared first on Myeloma Research News.

  • IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma
    by Mary Chapman on January 17, 2020 at 1:00 pm

    In partnership with Medscape Oncology, the International Myeloma Foundation (IMF) is offering a professional education series on continuous treatment in multiple myeloma, the foundation announced in a press release. Called “Everything You Need to Know About Continuous Treatment in Multiple Myeloma,” the series of online educational courses is targeted at hematology and oncology specialists, pharmacists The post IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma appeared first on Myeloma Research News.

Myeloma Research News The Web’s Daily Resource for Myeloma Research News

  • Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
    by Marisa Wexler, MS on January 27, 2020 at 1:00 pm

    Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of isatuximab when measuring levels of monoclonal protein — a marker of disease severity — in a person’s blood. Myeloma is a cancer of plasma cells, the type of cell responsible for making antibodies, or proteins that The post Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy appeared first on Myeloma Research News.

  • FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma
    by Patricia Inacio, PhD on January 24, 2020 at 3:00 pm

    The U.S. Food and Drug Administration (FDA) has granted priority review status to GlaxoSmithKline‘s application seeking the approval of belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company announced in a press release. The biologics license application (BLA) is specifically asking for belantamab’s approval for people with relapsed or refractory disease who received prior treatment The post FDA Grants Priority Review to Belantamab Mafodotin for Heavily-treated Multiple Myeloma appeared first on Myeloma Research News.

  • Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients
    by Patricia Inacio, PhD on January 21, 2020 at 3:29 pm

    The European Commission has approved Darzalex (daratumumab), in combination with standard pre-transplant therapy, to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT). The decision follows a positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, in December, recommending the approval of Darzalex in combination with Velcade (bortezomib), thalidomide, and The post Darzalex Combo Approved in Europe to Treat Transplant-eligible Myeloma Patients appeared first on Myeloma Research News.

  • NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients
    by David Melamed on January 20, 2020 at 1:00 pm

    NexImmune will soon initiate a Phase 1/2 trial evaluating its cell therapy NEXI-002 in people with multiple myeloma who failed three or more prior lines of therapy, the company announced. The announcement comes after the U.S. Food and Drug Administration cleared NexImmune’s investigational new drug (IND) application for NEXI-002, allowing it to enter clinical testing The post NexImmune to Initiate Phase 1/2 Trial of NEXI-002 Cell Therapy for RRMM Patients appeared first on Myeloma Research News.

  • IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma
    by Mary Chapman on January 17, 2020 at 1:00 pm

    In partnership with Medscape Oncology, the International Myeloma Foundation (IMF) is offering a professional education series on continuous treatment in multiple myeloma, the foundation announced in a press release. Called “Everything You Need to Know About Continuous Treatment in Multiple Myeloma,” the series of online educational courses is targeted at hematology and oncology specialists, pharmacists The post IMF, Medscape Oncology Offer Medical Education Series on Continuous Treatment in Myeloma appeared first on Myeloma Research News.